ALT-007 是一种口服有效的丝氨酸棕榈酰转移酶 (SPT) 抑制剂,可通过选择性降低毒性极长链脱氧鞘脂的水平来增强蛋白质稳态,从而恢复肌肉减少症小鼠模型中与衰老相关的肌肉质量损失,并在小鼠和秀丽隐杆线虫的衰老及疾病模型中均能增强蛋白质稳态,因此可用于与年龄相关的神经肌肉疾病的相关研究。
产品编号: MS-U45707 纯度: 99.81% CAS No.: 2035010-37-6 分子式: C25H26F3N5O5 分子量: 533.50
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

ALT-007 是一种口服有效的丝氨酸棕榈酰转移酶 (SPT) 抑制剂,可通过选择性降低毒性极长链脱氧鞘脂的水平来增强蛋白质稳态,从而恢复肌肉减少症小鼠模型中与衰老相关的肌肉质量损失,并在小鼠和秀丽隐杆线虫的衰老及疾病模型中均能增强蛋白质稳态,因此可用于与年龄相关的神经肌肉疾病的相关研究。

生物实验数据

生物活性 ALT-007 is an orally active serine palmitoyltransferase (SPT) inhibitor that enhances protein homeostasis by selectively reducing the levels of toxic very-long-chain deoxysphingolipids, thereby restoring aging-related muscle mass loss in a mouse model of sarcopenia; it also enhances protein homeostasis in aging and disease models in both mice and Caenorhabditis elegans, and can therefore be used in research related to age-related neuromuscular diseases.
IC50 & Target

SPT

体外研究
(In Vitro)

ALT-007 (10 nM-10 μM) 在 10 nM 的浓度下即可降低永生化小鼠 C2C12 成肌细胞中的神经酰胺水平,其效果与 Myriocin (MS-C89340) 相当。

体内研究
(In Vivo)

ALT-007 (1 mg/kg,口服 (混于食物中),每日一次,持续 20 周) 可增强肌少症老年小鼠模型的体能,体现在肌肉功能和有氧能力的提升。
ALT-007 (1 和 5 μM) 可改善跨物种的年龄相关的机能衰退,其通过调节蛋白质稳态来延长秀丽隐杆线虫的寿命并减轻蛋白质毒性作用。
ALT-007 (4 mg/kg,口服 (混于食物中),每日一次,持续 10 天) 在小鼠中具有良好的耐受性,并能有效降低肌肉神经酰胺水平。

Animal Model: Male C57BL/6J mice (18 months old)
Dosage: 1 mg/kg
Administration: p.o. (mixed with the food), daily for 20 weeks
Result: Improved muscle strength, as evidenced by increased maximum hanging time and grip strength compared to aged control mice after 7 and 8 weeks.
Improved coordination measured by the rotarod test in aged mice after 9 weeks.
Significantly increased VO2max and nightly energy expenditure.
Completely restored the age-related decline in overall physical activity to levels comparable to young mice.
Showed a non-significant trend toward improvement in uphill running endurance and post-exercise creatine kinase levels.
Showed stable body weight and no significant changes in food intake and in tissue weights relative to control.
Displayed no gastrointestinal (GI) toxicity compared to untreated controls.
Showed no difference in the glucose tolerance test compared to the aged control group.
Increased lean mass in aged mice, suggesting elevated muscle mass after 11 weeks.
Increased muscle weight in aged mice measured after 20 weeks.
Displayed lower levels of total ceramides in aged mice.
Impacted several age-related gene sets such as mitochondrial and proteostasis pathways, amino acids and biosynthetic processes, and neuronal-related gene sets.
Significantly attenuated ribosomal and translation pathways.
Promoted the enrichment of several proteostasis pathways (e.g., autophagy, unfolded protein response) in skeletal muscle of aged mice.
Resulted in remarkable upregulation of neurogenesis pathways in the muscle of aged mice.
Attenuated 1-Deoxy-SLs of very long chain, particularly 1-deoxyCer 22, 1-deoxyCer 24:1 and the sphingoid base N−C24:1-deoxysphinganine in the gastrocnemius muscle.
Attenuated the age-related increase in 1-deoxy-SLs in the brain.
Animal Model: C. elegans Strains (GMC-101, CL2120, and CL2122 as a control)
Dosage: 1 μM
Administration: from the embryonic stage
Result: Reduced paralysis induced by amyloid beta aggregation when assessed at day 1 of adulthood.
Decreased amyloid-beta protein aggregates.
Animal Model: Male C57BL/6J mice
Dosage: 4 mg/kg
Administration: p.o. (mixed with the food), daily for 10 days
Result: Showed no differences in body weight and food intake compared to DMSO control mice.
Displayed no hepatic or muscle toxicity, as indicated by plasma levels of transaminases (AST, ALT) and creatine kinase (CK) comparable to controls.
Effectively decreased ceramide levels in the gastrocnemius muscle, with a stronger effect on very long-chain (VLC) species.
Animal Model: C. elegans Strains (wild-type Bristol N2)
Dosage: 5 μM
Administration: starting from day 1 of adulthood
Result: Significantly increased median and maximal lifespan.
Was non-toxic for animal development when administered from the embryo stage, with animals exhibiting normal growth.
性状 固体
颜色 White to off-white

化学信息

分子量 533.50
分子式 C25H26F3N5O5
CAS No. 2035010-37-6

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (46.86 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.8744 mL9.3721 mL18.7441 mL46.8604 mL
5 mM0.3749 mL1.8744 mL3.7488 mL9.3721 mL
10 mM0.1874 mL0.9372 mL1.8744 mL4.6860 mL
15 mM0.1250 mL0.6248 mL1.2496 mL3.1240 mL
20 mM0.0937 mL0.4686 mL0.9372 mL2.3430 mL
25 mM0.0750 mL0.3749 mL0.7498 mL1.8744 mL
30 mM0.0625 mL0.3124 mL0.6248 mL1.5620 mL
40 mM0.0469 mL0.2343 mL0.4686 mL1.1715 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础